Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.
Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...
Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...
Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...
The device, Varipulse, is a pulsed field ablation system which uses small burns or freezes to cause some scarring in the ...
Irvine: Johnson & Johnson MedTech has announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE Platform ...
Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for ...
Background: Pulsed field ablation (PFA) has emerged as a safe and effective alternative to thermal ablation modalities for treatment of paroxysmal and persistent AF in a de novo procedure. Research ...
Pulsed-field ablation (PFA), which delivers high-voltage electric fields in microseconds, may limit this tissue damage outside the myocardium. However, the efficacy of pulsed-field ablation compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback